Schedule 13D ownership disclosure

Stoke Therapeutics Inc

Common Stock, $0.0001 par value per share · CUSIP: 86150R107

Event date: 2025-08-22

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Blue Horizon Enterprise LtdReported CIK 0001869057

    Shares: 1,967,621 · Class: 3.6%

  • Ezbon International LtdReported CIK 0001869027

    Shares: 288,560 · Class: 0.5%

  • Montrago Trustees LtdReported CIK 0001869331

    Shares: 2,256,181 · Class: 4.1%

  • Skorpios TrustReported CIK 0001869333

    Shares: 2,256,181 · Class: 4.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001123292-25-000387
Form type
SCHEDULE 13D/A
Filer
Skorpios Trust
CIK
CIK 1869333
Filed
Aug 26, 2025
Reporting period
Aug 22, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub